[go: up one dir, main page]

EP1115374A1 - Compositions contenant des composes phenoliques de mimosa - Google Patents

Compositions contenant des composes phenoliques de mimosa

Info

Publication number
EP1115374A1
EP1115374A1 EP00928906A EP00928906A EP1115374A1 EP 1115374 A1 EP1115374 A1 EP 1115374A1 EP 00928906 A EP00928906 A EP 00928906A EP 00928906 A EP00928906 A EP 00928906A EP 1115374 A1 EP1115374 A1 EP 1115374A1
Authority
EP
European Patent Office
Prior art keywords
skin
applying
composition according
composition
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00928906A
Other languages
German (de)
English (en)
Inventor
Jon E. Anderson
Lieve Declercq
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EL Management LLC
Original Assignee
EL Management LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EL Management LLC filed Critical EL Management LLC
Publication of EP1115374A1 publication Critical patent/EP1115374A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9739—Bryophyta [mosses]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • the present invention relates to topical cosmetic or pharmaceutical compositions. More specifically, the invention relates to cosmetic compositions containing compounds obtainable from Mimosa pudica , the compositions being useful in maintaining and/or increasing collagen levels in the skin.
  • Plants of the genus Mimosa are well-known and widespread throughout the tropical and subtropical regions of the world. Extracts of certain members of this genus, as well as the related genus Acacia , are known to have certain biological activities, for example, as an antispasmodic, astringent, antidiarrheal, and antirheumatic. Particularly well known in the species Mimosa tenuiflora , a shrub the bark of which has been used in the treatment of burns and the prevention of inflammation (Anton et al . , J. Ethnophar acol . 38: 153-157, 1993; FR 2710533).
  • M. pudica A less well-known species of Mimosa is M. pudica .
  • any proposed biological activity has been based on rooted primarily in ethnic medicine; suggested activities include a remedy for sleeplessness, spasms and convulsions of children.
  • M. pudica extracts exhibit useful anti-collagenase activity, which activity is based on a different class of compounds than those identified as actives in M. tenuiflora .
  • the present invention relates to topical cosmetic and pharmaceutical compositions comprising an effective amount of a biologically active phenolic compound-containing extract, or active fraction thereof, obtainable from Mimosa pudica .
  • Such compositions are useful in the maintenance and enhancement of collagen levels in the skin, and as such are useful in methods of preventing or treating fine lines and wrinkles, as well as preventing or treating the loss of skin firmness or elasticity, which are associated with chrono- and photoaging.
  • the composition contains at least one Mimosa pudica flavonoid, more preferably, at least C- glycosyl flavonoids, or a derivative thereof.
  • a phenol- containing extract of Mimosa pudica possesses strong biological activity, with the ability to maintain or enhance the levels of collagen in skin cells. More specifically, when provided to human fibroblasts, a phenolic-containing fraction of M. pudica can increase the collagen levels in these cells by as much as 100% or more, when provided at relatively low concentration. When the active extracts are treated to remove phenolics, the extract loses its activity
  • the biologically active extracts of M. pudica useful in this invention can be prepared by any means capable of extracting phenolic compounds from the plant material, using standard extraction techniques. Such extractions include, but are not limited to, ethanol, methanol, ethyl acetate, acetone, chloroform and water, or any other solvent and water. (Englert et al . , supra )
  • the active phenolic fraction can be obtained from any portion of the plant, but preferably the extract is taken from the aerial portions of the plant, including leaves, twigs, stem, or bark, as well as seeds.
  • pudica phenolics useful in the present invention are preferably flavonoids, such as dihydrorobinetin, fustin, fisetinedol, robinetinedol, catechin, gallocatechin, or epigallocatechin, and derivatives thereof (see, e.g., Cronje et al . , J. Chem. Soc. Perkin Trans. I: 2467-2477, or flavone aglycones, such as chysin, apigenin, luteolin, kaempferol, galangin, quercetin, rhamnetin, myricetin, gossypetin and the like.
  • flavonoids such as dihydrorobinetin, fustin, fisetinedol, robinetinedol, catechin, gallocatechin, or epigallocatechin, and derivatives thereof (see, e.g., Cronje et al . , J. Chem. Soc. Perkin Trans
  • the compounds are C- glycosyl flavones and aglycones thereof.
  • the preferred compounds are maysin, ax-4' ' -OH-maysin, 2"-0- rhamnosylorientin, and 2" -O-rhamnosyl isoorientin and the aglycone luteolin.
  • the phenolic compounds per se from whatever source they are obtainable.
  • C-glycosyl flavonoids are also obtainable and have been isolated from Zea mays (Snook et al . , Photochemistry 31: 1639-1647, 1992; Snook et al., J. Agric.
  • an effective amount of an extract, or an active portion thereof will depend on the purity of the source. For example, if a crude phenolic-containing extract of about 20% purity is employed, the extract will normally be used at a level of about 0.01-10% by weight of the composition. On the other hand, the higher the level of purity, the smaller the percentage required to achieve the same effect. Assuming a substantially pure phenolic extract (i.e., an extract containing at least about 90% active phenolics or flavonoids) , the concentration range will be about .001 to about 5% by weight of the composition, preferably about 0.01 to about 3%, most preferably about 0.1 to about 1%.
  • the extract or substantially pure flavonoids or flavonoid aglycones can be delivered in any form appropriate for topical application.
  • Such forms include solutions, colloidal dispersions, emulsions (oil-in-water or water-in-oil) , suspensions, powders, creams, lotions, gels, foams, mousses, sprays and the like.
  • Methodology for formulation of different vehicle types is well known in the art, and can be found for example in Remington's The Science and Practice of Pharmacy, 19th Edition, Volume II.
  • compositions of the invention are useful in the prevention or treatment of any condition in which the activity of collagenase and/or the reduction of collagen levels in the skin are a factor.
  • the compositions can be used to reduce the appearance of fine lines and wrinkles on the skin, due to either chrono- or photoaging.
  • the compositions are also useful in improving the firmness and elasticity of aging skin.
  • the compositions also have a number of therapeutic uses. One example is in the promotion of the process of wound healing.
  • the compositions can also be used in the treatment of conditions such as scleroderma, and keloids . Another use is the treatment of collagen-related conditions induced by topical and systemic drugs, e.g. corticosteroids and retinoids .
  • Topical corticosteroids are widely used for the treatment of inflammatory skin disorders, but the most common adverse effect is skin atrophy due to decreased collagen synthesis, and the present compositions can be used to treat or prevent the occurrence of atrophy.
  • the compositions can be applied directly to the skin in need of treatment in an amount of from about 0.1 ⁇ g/cm 2 to 2 mg/cm 2 of skin.
  • For cosmetic purposes e.g., for treatment or prevention of the symptoms of chrono- or photoaging, it is preferable that application be performed from about once per week to about 4 or 5 times daily, preferably from about 3 times a week to about 3 times daily, most preferably about once or twice per day.
  • the period of topical application may be over the lifetime of the user, preferably for a period of at least about one month, more preferably from about three months to about twenty years, more preferably from about six months to about ten years, more preferably still from about one year to about five years, thereby resulting in the treatment or prevention of the external signs of aging.
  • therapeutic uses such as wound-healing, drug- induced skin-atrophy, keloids and other collagen-related skin conditions, it will ordinarily be necessary to apply the compositions, on an as-needed basis, for example, once or twice daily, until relief of the symptoms is achieved.
  • the Mimosa pudica extract employed is a crude extract with 70% ethanol, obtained from Serdex.
  • Normal human dermal fibroblasts are seeded and grown to confluence in a 96-well plate prior to being treated with M. pudica extract or fractions thereof, prepared by solvent/solvent extractions (heptane/70% ethanol, ethyl acetate/water) at various concentrations in complete medium. Media alone serves as negative control and TGF- ⁇ serves as positive control. The plates are incubated for 4 days at 37°C/5% C0 2 before the supernatants are harvested and stored at -70°C until an ELISA is performed.
  • Antibodies to collagen type 1 or procollagen type 1 are used for ELISA analysis to determine collagen levels.
  • the results show an increase of 100% in collagen levels using the crude extract at 50 ppm; 118%, 142%, and 166%, for more refined fractions of the extract at 50 ppm, compared with 46% increase with 5ng/ml of TGF- ⁇ . This demonstrates the potent activity of M. pudica extracts in enhancing collagen levels.
  • a crude extract from the aerial parts of M. pudica is obtained by partitioning a heptane degreased 70% ethanol extract between ethyl acetate and water.
  • the nature of the anti-collagenase activity is already shown to be phenolic, as shown above.
  • the ethyl acetate extract is subsequently partitioned between butanol and acidified (pH5) water, the butanol residue is taken up in methanol and precipitated with ether and then undergoes a two-step fractionation procedure using preparative HPLC.
  • the anti-collagenase activity is evaluated and the most active fraction selected for further refinement. Compounds found in the most active fraction are identified as maysin and ax-4"-OH maysin.
  • the panelists are allowed to equilibrate for 30 minutes before commencement.
  • the following measurements are obtained: Fine lines and wrinkles, using silicone replicas obtained from the outer canthus area of both sides of the face at each visit; ultrasound imaging of the outer canthus area; skin firmness using a ballistometer .
  • the results indicate a 24% and 25% reduction, relative to baseline, in fine lines and skin wrinkles after 4 and 8 weeks respectively, with the extract.
  • the clarified samples show a 26% and 30% reduction at 4 and 8 weeks, respectively.
  • the vehicle is only 13% effective, a result possibly due to skin hydration.
  • Ultrasound indicates the most dense and least areas of the skin, presumed to be associated with higher concentrations of collagen and elastin.
  • An improvement in skin density is reflected as an increase in the denser areas and decrease in the thinner areas.
  • the vehicle is only effective at 19% and 16%.
  • thinner areas decrease by 15% and 14% with the extract, 21% and 18% with the clarified extract, and 15% and 7% with the vehicle.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des compositions topiques cosmétiques et pharmaceutiques servant à augmenter les niveaux de collagène dans les cellules de la peau et comprenant une quantité efficace d'un extrait biologiquement actif contenant un composé phénolique, ou une fraction active de ce dernier, produit par Mimosa pudica.
EP00928906A 1999-07-23 2000-05-08 Compositions contenant des composes phenoliques de mimosa Withdrawn EP1115374A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36084499A 1999-07-23 1999-07-23
US360844 1999-07-23
PCT/US2000/012518 WO2001007008A1 (fr) 1999-07-23 2000-05-08 Compositions contenant des composes phenoliques de mimosa

Publications (1)

Publication Number Publication Date
EP1115374A1 true EP1115374A1 (fr) 2001-07-18

Family

ID=23419627

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00928906A Withdrawn EP1115374A1 (fr) 1999-07-23 2000-05-08 Compositions contenant des composes phenoliques de mimosa

Country Status (3)

Country Link
EP (1) EP1115374A1 (fr)
HK (1) HK1038700A1 (fr)
WO (1) WO2001007008A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4880816B2 (ja) * 2000-12-15 2012-02-22 株式会社ヤクルト本社 皮膚老化防止剤
AUPR870501A0 (en) * 2001-11-07 2001-11-29 Biotech Research Ventures Pte Limited Composition containing a flavonoid glycone and method for using same as anti-proliferative
FR2835427B1 (fr) * 2002-02-04 2006-08-04 Nuxe Lab Composition cosmetologique et/ou dermatologique a base d'extrait de barbatimao
KR100720973B1 (ko) * 2005-03-18 2007-05-22 주식회사 유니젠 천연물 유래 아이소오리엔틴을 포함하는 히스타민 억제용약학 조성물
EP2046281B1 (fr) * 2006-06-16 2014-08-13 Societe De Recherche Cosmetique Utilisation d'un extrait de graines de mimosa (d'acacia dealbta, d'acacia farnesiana ou d'acacia decurrens) dans une composition cosmetique
FR2902335B1 (fr) * 2006-06-16 2010-09-10 Nuxe Lab Utilisation d'un extrait de mimosa dans une composition cosmetique.
JP2007056035A (ja) * 2006-10-19 2007-03-08 Fancl Corp 正常ヒト表皮角化細胞の分化抑制剤
CN112168815A (zh) * 2018-08-30 2021-01-05 中国科学院分子植物科学卓越创新中心 黄酮碳苷单体化合物的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2578422B1 (fr) * 1985-03-05 1987-06-26 Cariel Leon Composition de traitement a usage topique externe a base de luteoline et procede de preparation
EP0329834A3 (fr) * 1988-01-28 1989-11-29 Francisco José Izundegui MacDonnell Composition pour la régénération et repousse des cheveux, curative et germicide pour la peau et les muqueuses
ES2012104A6 (es) * 1988-06-28 1990-03-01 Perez Julio Tellez Procedimiento para la extraccion y aislamiento del principio activo regenerador epidermal de la mimosa tenuiflora y composicion cosmetica que lo contiene.
DE19641992C2 (de) * 1996-10-13 2001-07-26 Wella Ag Blütenwachs enthaltende kosmetische Zubereitungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0107008A1 *

Also Published As

Publication number Publication date
HK1038700A1 (zh) 2002-03-28
WO2001007008A1 (fr) 2001-02-01

Similar Documents

Publication Publication Date Title
US6290993B1 (en) Compositions containing mimosa phenolic compounds
Elgamal et al. Phytochemical profiling and anti-aging activities of Euphorbia retusa extract: in silico and in vitro studies
KR20090057971A (ko) 멘얀테스 트리폴리아타 잎 추출물을 포함하는 항-노화 조성물 및 그의 사용 방법
JP2004517836A (ja) 植物アルガニア・スピノーザの葉抽出物を含有する化粧品および／または皮膚薬調製物
KR102833257B1 (ko) 케이폭 나무 꽃 추출물, 및 이를 함유하는 미용적, 약학적 또는 피부학적 조성물
KR20100042279A (ko) Ａｇｅ 형성의 억제
JPH10279491A (ja) インターロイキン４産生抑制剤
JP2011246353A (ja) 皮膚外用剤
CN102370591A (zh) 石榴皮提取方法及其提取物的应用
JP2003002819A (ja) 皮膚組成物
RU2571075C2 (ru) Композиции, содержащие павловнин и/или экстракты павловнии, и их использование
WO2001007008A1 (fr) Compositions contenant des composes phenoliques de mimosa
ES2567131T3 (es) Extracto de Vanilla planifolia, procedimiento para su obtención, y composición cosmética o dermatológica que locontiene
KR20150003193A (ko) 화장품 및 제약 조성물에 플라보노이드를 포함하는 엠벨리아 콘신나 추출물
US20110135772A1 (en) Skin care agent and compositions thereof
KR101757674B1 (ko) 도깨비바늘 추출물을 유효성분으로 함유하는 피부 탄력 증진 및 피부 주름 개선용 화장료 조성물
AU2014233649A1 (en) Compositions comprising Paulownia tomentosa wood extracts and uses thereof
JP2008525462A (ja) しわの外観を減少させるための方法および組成物
US20130028849A1 (en) Agent For Stimulating The Expression of Loxl
KR100787783B1 (ko) 스코폴레틴을 유효성분으로 함유하는 피부주름 개선용 화장료 조성물
KR101972073B1 (ko) 시링가레시놀을 포함하는 노화 억제용 조성물
KR20020061196A (ko) 황금 추출물을 함유하는 화장료 조성물
KR20160112546A (ko) 시링산을 유효성분으로 포함하는 피부상태 개선용 조성물
KR102761304B1 (ko) 업사이클링 자이언트 병풀 추출물을 유효성분으로 포함하는 피부 개선용 조성물 및 이의 제조방법
KR101697236B1 (ko) 상지의 분배추출물을 유효성분으로 함유하는 화장료 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010322

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20061220

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 36/48 20060101ALI20080312BHEP

Ipc: A61K 8/97 20060101AFI20080312BHEP

Ipc: A61K 8/49 20060101ALI20080312BHEP

Ipc: A61K 8/60 20060101ALI20080312BHEP

Ipc: A61Q 19/00 20060101ALI20080312BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080812

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1038700

Country of ref document: HK